schedule of drugs with short half life is usually three or even
four times a day. This is obviously very inconvenient. An extended
release drug delivery with a mono-phasic drug release from the matrix
usually doesn't provide a pharmacokinetic profile which provides
meaningful therapeutic action. To provide therapeutically meaningful
extended delivery of such drugs, Troikaa has developed the Duophase
Technology. Through this technology, the drug dose is split judiciously
into two components, where one part delivers the drug immediately
and the other releases the drug in a sustained release pattern.
Thus, the drug delivery is biphasic and ensures the requisite pharmacokinetic
profile. Drugs developed using this technology are extended release
Paracetamol tablets of 650mg. and 1000mg. (Xykaa Extend) and extended
release Ibuprofen tablets of 600 mg.
Products manufactured using Duophase Technology are presented in
stylised tablets which graphically represent the biphasic drug delivery.